Építés alatt – nem éles oldal
Belépés
Fut, nem toboroz1/2. fázis

Safety and Efficacy of Voxzogo for Growth Deficits in MPS IVA and VI

A legfontosabb adatok

Ki végzi
University of California, San Francisco
Hol
Oakland (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Fut, nem toboroz
Fázis
1/2. fázis
Résztvevők
6 fő vett részt
Kezdés
2023. szept. 25.
Várható befejezés
2029. dec. 31.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Vosoritide Injection [Voxzogo]
A regiszteradat frissítve
2026. március 10.

Ki vehet részt

Életkor
5 év – 10 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 33 feltétel megnézéseKevesebb

Ki vehet részt

  • Age >= 5 years and < 10 years
  • Tanner stage 1
  • Clinical Diagnosis of MPS IVA or VI; Subjects will be stratified into 2 groups:
  • MPS IVA (3 patients)
  • MPS VI (3 patients); MPS Diagnosis Confirmed by either:; Demonstration of 2 pathogenic or likely pathogen mutations (or homozygous for single mutation) and elevated GAG (either before or during ERT treatment), OR; Demonstration of diagnostic enzyme deficiency, elevated GAG (either before or during ERT treatment), and a normal second sulfatase; Currently receiving ERT [elosulfase alfa (Vimizim®) or galsulfase (NAGLAZYME®)] for minimum of 12 months prior to study entry; HSCT greater than 3 years before entry; Height Z-score <-2.0 or less than 2 cm change in height velocity over the last 1 year; Willing to consent to the study and comply with all study procedures and assessments; Able to stand independently without hand support for minimum of one minute; Guardians able to successfully administer investigational drug daily/SQ

Ki nem vehet részt

  • Receiving or has previously received a GnRH analog (e.g. leuprolide acetate, histrelin)
  • Concurrent participation on an investigational drug trial
  • Investigational drug washout minimum of 5 half-lives of the drug or 1 month whichever is longer
  • Previous or current treatment with the investigational drug (vosoritide)
  • Known or suspected allergy to the investigational drug (vosoritide)
  • Bone fracture within the previous 6 months
  • Skeletal surgery within the previous 6 months, or anticipated significant surgery (in the view of the investigator) during course of the study
  • Spine curvature (scoliosis) on previous x-ray greater than 25 degrees
  • Treated with chronic oral steroids in previous 6 months
  • Concurrent disease or condition that in the view of the investigator, would interfere with study participation or safety evaluations, for any reason
  • History of malignancy
  • History of chronic inflammatory condition not related to MPS
  • History of conditions/medical therapies that might affect the interpretation of growth results such as anemia, celiac disease, diabetes, inflammatory bowel disease, and cystic fibrosis
  • History of gene therapy
  • Any history of bone lengthening surgeries or spine fixation surgery
  • Illness that could affect blood pressure / orthostatic problems
  • Receiving or has received growth hormone therapy, IGF-1 therapy, anti-TNF alpha therapy, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers, diuretics, beta-blockers, calcium channel blockers, cardiac glycosides, systemic anticholinergic agents, any medication that may impair or enhance compensatory tachycardia, diuretics or other drugs known to alter renal or tubular function within the previous 6 months
  • QTC (Fridericia) > 450 msec
  • History of chronic renal insufficiency, defined previously as an eGFR <60 mL/min/1.73m2
  • Treated with medications known to affect QC/QTc
  • LV Ejection fraction <40%; LVEF=[SV/EDV] x100 (American Society Echocardiography)
  • Diagnosis with growth hormone deficiency (defined by IGF-1 SDS <-1.0 according to age, gender and tanner stage)
  • ERT naïve
  • Poor compliance with ERT (<75% in 6 month period)
  • Hypothyroidism, untreated (TSH >4.0 mU/L)
  • Malnutrition (BMI <5th percentile)
  • Untreated severe sleep apnea
  • Mean SpO2 of < 92% at baseline, taken from average of 3 measurements in each hand

Helyszínek itt: Egyesült Államok

  • UCSF Benioff Children's Hospital OaklandOakland, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a Phase I/II, single arm, open label study of vosoritide therapy provided subcutaneously at 15 ug/kg/day for 96 weeks to 6 patients with MPS IVA or VI. Prior to enrollment in the interventional arm of study, subjects will be followed for a minimum of 24 weeks to gather information on safety profiles and determine annualized growth velocity. The primary study endpoint is the determination of safety and tolerability of daily vosoritide treatment in MPS. Exploratory endpoints include changes in linear and segmental growth as well as biomarkers of growth and bone metabolism.

A vizsgálat csoportja

  • VosoritideEgyéb csoport

    This is a single arm open label study of daily SQ dose of vosoritide

    Kezelés: Vosoritide Injection [Voxzogo]

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Proof of Concept Study to Evaluate the Safety and Efficacy of Voxzogo (Vosoritide) for the Treatment of Growth Deficits in MPS IVA and VI
A regiszteradat frissítve
2026. március 10.